☆ 4.5 Article

Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond

Angela Sciacqua et al.

Summary: Heart failure and type 2 diabetes are two important public health problems, especially among the elderly. Certain antidiabetic drugs should be used with caution in elderly individuals due to the risk of hypoglycemia and fluid retention. GLP-1 RAs and SGLT2 inhibitors have shown positive effects on cardiovascular outcomes. Treatment of diabetic elderly patients with heart failure should be based on scientific evidence, clinical judgment, and consideration for their dignity and quality of life.

HEART FAILURE REVIEWS (2023)

Add to Collection

Article Peripheral Vascular Disease

DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment

Jessica R. Wilson et al.

Summary: DPP4 inhibition may increase catecholamine levels, but does not increase blood pressure. Increased catecholamines during concurrent use of ACE and DPP4 inhibitors may contribute to cardiovascular complications in patients predisposed to heart failure.

HYPERTENSION (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone

Imre Voros et al.

Summary: DPP4 inhibitors are a new type of medication for treating diabetes, but the use of saxagliptin may increase hospitalization for heart failure. The mechanism behind this potential cardiotoxicity is unclear. In this study, a cellular platform was established to investigate the effects of DPP4 inhibition and its neuropeptide substrates on the human heart. The expression of DPP4 and its neuropeptide substrates in heart failure patients was also examined. The results showed decreased expression of DPP4 and NPY in heart failure patients, suggesting their involvement in the pathophysiology of end-stage heart failure.

BIOMEDICINES (2022)

Add to Collection

Editorial Material Endocrinology & Metabolism

Heart failure: now centre-stage in diabetes

John J. McMurray et al.

LANCET DIABETES & ENDOCRINOLOGY (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes

Nikolaus Marx et al.

Summary: Multiple large cardiovascular outcome trials have shown that SGLT2 inhibitors and GLP-1 receptor agonists significantly reduce cardiovascular disease risk in patients with type 2 diabetes, including major adverse cardiovascular events and heart failure. These drugs have received strong recommendations in diabetes and cardiology guidelines, but their usage remains low.

CIRCULATION (2022)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Naveed Sattar et al.

Summary: The meta-analysis showed that GLP-1 receptor agonists can reduce the risk of major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes, regardless of structural homology.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Diabetes Management in Patients with Heart Failure

Jia Shen et al.

Summary: Diabetes and heart failure are common diseases with increasing prevalence rates, often co-existing in patients and complicating management. There is evidence that managing diabetes can impact heart failure events, even in non-diabetic patients.

DIABETES & METABOLISM JOURNAL (2021)

Add to Collection

Review Endocrinology & Metabolism

Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction

Farah Hamad et al.

Summary: The FIGHT and LIVE trials demonstrate that the use of liraglutide in patients with heart failure and rLVEF is not significantly effective, and is associated with an increased risk of adverse heart failure-related outcomes.

CURRENT DIABETES REVIEWS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure

Petar M. Seferovic et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Darren K. McGuire et al.

CIRCULATION (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cardiovascular Effects of New Oral Glucose-Lowering Agents DPP-4 and SGLT-2 Inhibitors

Andre J. Scheen

CIRCULATION RESEARCH (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure

John J. V. McMurray et al.

JACC-HEART FAILURE (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Analysis of the Correlation between the Myocardial Expression of DPP-4 and the Clinical Parameters of Patients with Heart Failure

Yuka Kobara et al.

INTERNATIONAL HEART JOURNAL (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dipeptidyl peptidase-IV in chronic heart failure with reduced ejection fraction

Patricia Lourenco et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failure - Insights From the Ibaraki Cardiac Assessment Study-Heart Failure (ICAS-HF) Registry -

Masayoshi Yamamoto et al.

CIRCULATION JOURNAL (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus Secondary Analysis of a Randomized Clinical Trial

Darren K. McGuire et al.

JAMA CARDIOLOGY (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus

Akihiko Sato et al.

ESC HEART FAILURE (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure

Ayako Takahashi et al.

International Heart Journal (2015)

Add to Collection

Article Medicine, General & Internal

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

Faiez Zannad et al.

LANCET (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure

S. Paolillo et al.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Benjamin M. Scirica et al.

CIRCULATION (2014)

Add to Collection

Article Cardiac & Cardiovascular Systems

Sitagliptin Use in Patients With Diabetes and Heart Failure A Population-Based Retrospective Cohort Study

Daniala L. Weir et al.

JACC-HEART FAILURE (2014)

Add to Collection

Article Cardiac & Cardiovascular Systems

Circulating Dipeptidyl Peptidase IV Activity Correlates With Cardiac Dysfunction in Human and Experimental Heart Failure

Leonardo dos Santos et al.

CIRCULATION-HEART FAILURE (2013)

Add to Collection

Article Medicine, General & Internal

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular Biology of the Incretin System

John R. Ussher et al.

ENDOCRINE REVIEWS (2012)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

Nelson Gomez et al.

EUROPEAN JOURNAL OF HEART FAILURE (2012)

Add to Collection

Article Hematology

Clopidogrel 150 vs. 75 mg day-1 in patients undergoing percutaneous coronary intervention: a meta-analysis

P. P. Hao et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)

Add to Collection

Article Cardiac & Cardiovascular Systems

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

Que Liu et al.

CARDIOVASCULAR DIABETOLOGY (2010)

Add to Collection

Article Medicine, General & Internal

Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis

Simon McRae et al.

LANCET (2006)

Add to Collection

Article Neurosciences

Insulin signalling and resistance in patients with chronic heart failure

J Kemppainen et al.

JOURNAL OF PHYSIOLOGY-LONDON (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.